Myriad Genetics, Inc. (MYGN) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. Myriad Genetics, Inc. is a leading genetic testing and precision medicine company operating as a single reporting segment. The company focuses on Oncology, Women's Health, and Pharmacogenomics. The filing notes that the third quarter is typically weaker due to seasonal factors such as patient deductible resets and summer vacation schedules.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Testing Revenue | $213.3M | $191.9M | $627.0M | $556.6M |
| Net Loss | $(22.1M) | $(61.3M) | $(84.8M) | $(232.1M) |
| Operating Loss | $(20.0M) | $(60.1M) | $(84.5M) | $(226.0M) |
| Diluted EPS | $(0.24) | $(0.75) | $(0.94) | $(2.84) |
| Cash & Equivalents | $99.9M | $76.0M | $99.9M (End of Period) | $85.0M (End of Period) |
| Long-Term Debt | $39.0M | $38.5M | $39.0M | $38.5M |
| Operating Cash Flow (9M) | $(15.3M) | $(56.2M) | $(15.3M) | $(56.2M) |
Margins: Cost of testing revenue was 29.8% of total revenue in Q3 2024 (vs. 30.0% in Q3 2023). Gross margin improved slightly to 70.2%.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 11% year-over-year, driven by a 6% increase in testing volumes and higher average revenue per test. Pharmacogenomics revenue grew 34% ($12.0M increase) due to volume and pricing changes. Hereditary Cancer and Prenatal revenues also increased.
- Profitability Improvement: Net loss narrowed significantly from $61.3M in Q3 2023 to $22.1M in Q3 2024. This improvement is largely attributable to the absence of $34.3M in legal settlement charges recorded in Q3 2023.
- Impairment Charges: The company recorded $2.2M in goodwill and long-lived asset impairment charges in Q3 2024, primarily related to the sale of the EndoPredict business. No such charges were recorded in Q3 2023.
- Divestiture: In August 2024, the company sold its EndoPredict business for net cash of $10.0M, recognizing a net loss of $12.4M on the transaction.
- Acquisition: In February 2024, the company acquired assets from Intermountain Health (Precise Tumor Test) for an immaterial amount, recognizing a $2.2M gain.
Guidance, Outlook, and Risks
- UnitedHealthcare Policy Change: On November 1, 2024, UnitedHealthcare updated its medical policy to no longer cover certain multi-gene panel pharmacogenetic tests, including Myriad's GeneSight, under commercial and individual exchange plans effective January 1, 2025. Myriad recognized approximately $40.0M in GeneSight revenue from these plans in the last 12 months. Management anticipates this will negatively impact revenue in fiscal year 2025 and thereafter.
- Goodwill Impairment Risk: Due to the UnitedHealthcare policy change, the Pharmacogenomics reporting unit (holding ~42.3% of total goodwill) may be at risk of future impairment. The company is assessing the full impact on long-term forecasts.
- Liquidity: As of September 30, 2024, the company had $99.9M in cash and $48.8M in availability under its $115.0M asset-based revolving credit facility (ABL). Management believes existing resources are sufficient for the next 12 months.
- Legal Proceedings: A global stipulation of settlement was reached regarding stockholder derivative actions, with the company accruing $0.95M for legal fees. A ruling is expected in late November 2024.
- Seasonality: The company expects the fourth quarter to be stronger due to patients meeting deductibles, though the UnitedHealthcare policy change introduces uncertainty.
Investor Verification Checklist
- Verify the specific impact of the UnitedHealthcare policy change on Q4 2024 and FY 2025 revenue guidance, particularly for the GeneSight product line.
- Monitor the outcome of the stockholder derivative settlement ruling expected in late November 2024.
- Assess the potential for future goodwill impairment charges related to the Pharmacogenomics reporting unit.
- Review the company's strategy to offset the loss of UnitedHealthcare coverage, including potential new payor contracts or product launches (e.g., FirstGene, Precise Liquid).
- Confirm the status of the $18.2M future rent commitment for the expanded west Salt Lake City facility commencing in 2026.